Joanne Lagmay | Research | University of Florida

Skip to main content All experts

CHIEF & CLIN PROF

MD-PEDIATRICS

CHIEF & CLIN PROF
MD-PEDIATRICS

jplagmay@peds.ufl.edu (opens in a new tab)

sort by:

GRANT
Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
H Lee Moffitt Cancer Center & Research Institute31 May 2027 - 23 Sep 2026
Active
GRANT
BCC020: A Dose Escalation Study Using Difluoromethylornithine (DFMO) and AMXT-1501 Followed by a Randomized Controlled Trial of DFMO With or Without AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Beat Childhood Cancer26 Feb 2026 - 25 Feb 2031
Active
GRANT
Metastatic Ewings Trial Testing Schedule Enhancement to Improve Outcomes
National Pediatric Cancer Foundation5 Nov 2025 - 4 Nov 2030
Active
GRANT
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Beat Childhood Cancer6 May 2025 - 5 May 2030
Active
GRANT
A PHASE II, RANDOMIZED, OPEN-LABEL STUDY TO ASSESS THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF MAINTENANCE CABOZANTINIB (XL184) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS BSC IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS (AYA) WITH UNRESECTABLE RESIDUAL OSTEOSARCOMA EITHER AT DIAGNOSIS OR AT FIRST RELAPSE AFTER STANDARD TREATMENT
Ipsen Biopharmaceuticals19 Nov 2024 - 2 Feb 2026
Closed
GRANT
A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma
Y-Mabs Therapeutics Inc22 Sep 2023 - 8 Jun 2028
Active
GRANT
Adapting the Healthy Communication Practice Program for Parent Caregivers of Adolescents and Young Adults (AYAs) Living with a Blood Cancer
Blood Cancer United7 Jun 2023 - 31 May 2025
Expired
GRANT
Towards liquid biopsy for pediatric sarcoma
Florida Department of Health Live Like Bella6 Jun 2023 - 31 Mar 2026
Expired
GRANT
A Phase 1/2 Dose Escalation and Dose Expansion Study of ZN-c3 in Combination with Gemcitabine in Adult and Pediatric Subjects with Relapsed or Refractory Osteosarcoma
K-Group Beta19 Jul 2022 - 13 Feb 2024
Closed
GRANT
Point-of-care intervention to address financial toxicity in families facing pediatric cancer
Florida Department of Health Live Like Bella1 Feb 2022 - 30 Sep 2024
Expired
GRANT
AOST-2121, Protocol OST31-164-01, An Open-Label Phase 2 Study of Maintenance Therapy with OST31-164 After Resection of Recurrent Osteosarcoma.
Os Therapies4 Nov 2021 - 1 Jul 2023
Expired
GRANT
Phase ½ Study of Bempegaldesleukin in combination with Nivolumab in Children, Adolescents, and young Adults with Recurrent or Refractory Malignancies
Bristol Myers Squibb Corporation4 Nov 2021 - 8 Sep 2022
Closed
GRANT
Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albuminbound Nanoparticles for Injectable Suspension) in Patients with Advanced Perivascular Epithelioid Cell Tumors (PEComa) and Patients with a Malignancy with Relevant Genetic Mutations or mTOR Pathway Activation
Aadi Bioscience23 Jun 2021 - 11 May 2022
Closed
GRANT
Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
Florida Department of Health Live Like Bella9 Apr 2021 - 19 Jul 2023
Closed
GRANT
Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
National Pediatric Cancer Foundation9 Apr 2021 - 19 Jul 2023
Closed
GRANT
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)#
Pennsylvania State University10 Dec 2020 - 31 Jan 2027
Active
GRANT
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
Atrium Health10 Dec 2020 - 23 Sep 2023
Closed
GRANT
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma#
Florida Department of Health Live Like Bella15 Nov 2019 - 30 Apr 2027
Active
GRANT
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma
Florida Department of Health6 Nov 2019 - 31 Dec 2024
Closed
GRANT
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma
National Pediatric Cancer Foundation6 Nov 2019 - 31 Dec 2024
Expired
GRANT
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma#
National Pediatric Cancer Foundation6 Nov 2019 - 30 Apr 2027
Active
GRANT
A Phase 3 Trial of Antibody hu3F8 and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary or Secondary Refractory Osteomedullary Disease
Y-Mabs Therapeutics Inc7 Dec 2018 - 11 Jul 2023
Closed
GRANT
Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
H Lee Moffitt Cancer Center & Research Institute31 May 2017 - 15 May 2022
Closed
GRANT
A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan and Temozolomide in Chidlren with RElapsed or Refractory Solid Tumors
Pediatric Cancer Research Foundation22 Nov 2013 - 24 Jun 2016
Expired

DrJoanne Lagmay

GRANTS